A Case of Erythrodermic Dermatomyositis Associated with Gastric Cancer

Sung Woo Kim, M.D., Yoo Seok Kang, M.D., Sang Hoon Park, M.D., Un Ha Lee, M.D., Hyun Su Park, M.D., Sang Jai Jang, M.D.

Department of Dermatology, Sanggye Paik Hospital, Inje University College of Medicine, Seoul, Korea

Erythroderma is an unusual cutaneous finding associated with dermatomyositis. There are only five cases of erythrodermic dermatomyositis reported in the English literature. We treated a case of erythrodermic dermatomyositis associated with a Bormann type 1 gastric cancer. The patient had a generalized, erythematosus scaly eruption consistent with erythroderma and Gottron’s papules as well as a heliotrope rash; these are the hallmark skin manifestations of dermatomyositis. (Ann Dermatol 21(4) 435~439, 2009)

-Keywords-
Dermatomyositis, Erythroderma, Gastric cancer, Malignancy

INTRODUCTION

Dermatomyositis is a rare systemic autoimmune disorder characterized by specific cutaneous manifestations and symmetric proximal muscle weakness. In addition to the skin and skeletal muscles, a variety of internal organs, such as the heart, lung, gastrointestinal tract, and eyes, can also be affected. Life threatening complications can develop including internal malignancies, calcinosis, and vasculopathy. Erythroderma is defined as a diffuse scaly erythema of the skin involving more than 90 percent of the total body skin surface area. It can be caused by a variety of cutaneous and systemic diseases. It has been reported that pre-existing skin diseases including psoriasis, atopic dermatitis, drug reactions, seborrheic dermatitis, and congenital dermatoses play a role in the development of erythroderma in approximately 52% of the cases. In addition, a variety of drugs and malignancies, including solid tumors and lymphoproliferative diseases, can cause erythroderma. Among the malignancies, cutaneous T-cell lymphoma is the most common cause of erythroderma. In cases of paraneoplastic erythroderma, the cutaneous finding of erythroderma may occur as the only symptom of a malignancy. Therefore, patients with a history of recurrent erythroderma without a known cause should be evaluated periodically for an occult malignancy. Erythroderma can present as a cutaneous finding associated with dermatomyositis; however, this is unusual. We could find only five cases of erythrodermic dermatomyositis in the English literature (Table 1). Among the documented cases, two were associated with internal malignancies of the stomach and liver. Here we report a case of erythrodermic dermatomyositis associated with gastric cancer.

CASE REPORT

A 90-year-old male with a 10-year history of generalized pruritus presented with aggravation of his skin lesions and weakness of the proximal extremities. The skin lesions were observed as violaceous to erythematous, confluent, scaly patches involving more than 90 percent of the total body area. Periorbital, edematous, violaceous erythema and scaly papules affecting the extensor aspects of the interphalangeal joints of the hands were noted. The patient complained of worsening of the skin lesions and pruritus after exposure to sunlight. In addition, he complained of difficulty in raising his hands over the level of his shoulders, sitting down on a chair and standing up, which started six years ago and has gradually worsened.
Table 1. Reported cases of erythrodermic dermatomyositis

<table>
<thead>
<tr>
<th>Authors (year)</th>
<th>Sex/Age</th>
<th>Onset of the symptoms before diagnosis</th>
<th>Systemic involvement</th>
<th>Concomitant internal organic malignancy</th>
<th>Treatment</th>
<th>Progression</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ramirez et al. (1990)</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
</tr>
<tr>
<td>Miyagawa et al. (1992)</td>
<td>F/73</td>
<td>6 WA</td>
<td>Dysphagia</td>
<td></td>
<td>Systemic steroid</td>
<td>Well controlled with prednisolone, 15 mg/day after 1 year of treatment</td>
</tr>
<tr>
<td>Nousari et al. (1998)</td>
<td>M/64</td>
<td>6 MA</td>
<td></td>
<td>Gastric cancer</td>
<td>Systemic steroid</td>
<td>Died four months after the initial hospitalization</td>
</tr>
<tr>
<td>Maruani et al. (2003)</td>
<td>M/64</td>
<td>3 MA</td>
<td>Lymphadenopathy</td>
<td>Hepatocellular carcinoma</td>
<td>Systemic steroid + Tamoxifen</td>
<td>Died two months after the initial hospitalization</td>
</tr>
<tr>
<td>Liu and Wang (2007)</td>
<td>M/50</td>
<td>1 WA</td>
<td>Orbital myositis</td>
<td>Interstitial lung disease</td>
<td>Systemic steroid + IVIG</td>
<td>Remission of symptoms after 5 days of therapy</td>
</tr>
<tr>
<td>This case</td>
<td>M/90</td>
<td>10 YA</td>
<td></td>
<td>Gastric cancer</td>
<td>Conservative treatment</td>
<td>Died four months after the initial hospitalization</td>
</tr>
</tbody>
</table>


Histopathology of the erythematous scaly patch showed epidermal atrophy, hydropic degeneration of the basal cell layer, papillary dermal edema, and a mild dermal perivascular lymphocytic infiltration (Fig. 3). Laboratory investigations demonstrated elevated serum creatine kinase (452 U/L, reference: 25 ∼ 90 U/L), lactate dehydrogenase (587 U/L, reference: 100 ∼ 190 U/L), and aspartate transaminase levels (68 U/L, reference: 0 ∼ 35 U/L). The electromyography revealed short duration muscle unit action potentials in the deltoid and iliopsoas muscles. A muscle biopsy of the deltoid muscle showed small atrophic myofibers and focal inflammatory infiltration suggestive of an inflammatory myopathy. Additional history revealed a medical history of untreated gastric cancer that was diagnosed five years previously. The gastroendoscopy showed a Bormann type 1 gastric cancer. The patient was transferred to the neurology department and conservative management was provided for the diagnosis of dermatomyositis. Two months later, the patient died of complications associated with interstitial lung disease and a malignant pleural effusion.

**DISCUSSION**

The idiopathic inflammatory myopathies are a heterogeneous group of autoimmune disorders that predominately target the skin and skeletal musculature. This term previously referred to cases with polymyositis/dermatomyositis. The idiopathic inflammatory myopathy classification system does not include cutaneous-only (amopathic) or cutaneous predominant (hypomyopathic) subsets of dermatomyositis. Clinically amopathic dermatomyositis is a designation that refers both to amopathic and hypomyopathic dermatomyositis. As the hallmark cutaneous skin lesions are the only clue to the diagnosis of dermatomyositis until the myopathic symptoms become evident; dermatologists are especially interested this type of dermatomyositis. From this point of view, Sontheimer proposed a more inclusive categorization of disease referred to as ‘idiopathic inflammatory dermatomyopathies’ encompassing the subset of clinically amopathic dermatomyositis.

In the case presented here, the diagnosis of dermatomyositis was made using the criteria of Bohan et al. including the typical skin rash, symmetrical proximal muscle weakness with or without dysphagia or respiratory muscle involvement, abnormal findings on the muscle biopsy specimen, elevation of the skeletal muscle-derived enzymes, and abnormal electromyogram. If more than four criteria, as described above, are fulfilled, a definite diagnosis of dermatomyositis can be made. The patient presented here met all of the above criteria. The hallmark skin manifestations include heliotrope rash and Gottron’s papules; these are characteristic and pathognomonic cutaneous findings associated with dermatomyositis. Other cutaneous features include poikiloderma, malar erythema, periangual telangiectasia, and photosensitivity.

There are five reported cases of dermatomyositis presenting as erythroderma in the English literature (Table 1). Even though only a few cases have been reported in the literature, erythroderma is not likely to be a rare form of dermatomyositis. Maruani et al. suggested that the terms used in previous reports, ‘widespread erythema’, ‘diffuse rash’, and ‘generalized eczema’ were describing cases with erythroderma. In addition, it is noteworthy that two of the five documented cases were asso-
associated with internal malignancies, gastric cancer\(^4\) and hepatocellular carcinoma\(^6\). It is well known that dermatomyositis is highly associated with malignancies\(^1,2\). Since the concomitant malignancy indicates a poor prognosis with dermatomyositis\(^1\), many studies have attempted to identify the clinical features associated with a greater risk of malignancy in patients with dermatomyositis. Advanced age\(^2\), normal serum creatine kinase level\(^13\), increased erythrocyte sedimentation rate\(^14\), presence of cutaneous vasculitis\(^15\), and cutaneous necrosis\(^14\) are risk factors. However, these risk factors have not been confirmed by all studies. For example, Fudman and Schnitzer\(^13\) reported that a normal creatine kinase level was associated with a poor prognosis. However, Sparsa et al.\(^16\) reported that patients with a higher level of creatine kinase were more likely to have cancer.
Fig. 2. Hallmark cutaneous skin manifestations of dermatomyositis including (A) heliotrope rash and (B) Gottron’s papules were noted.

Fig. 3. Histopathology of the skin lesion showed a hyperkeratotic stratum corneum, epidermal atrophy, hydropic degeneration of the basal cell layer, papillary dermal edema, dermal mild perivascular lymphocytic infiltration and increased mucin deposition (H&E, A: ×40, B: ×200).

Maruani et al.\textsuperscript{6} proposed that erythroderma was a predictive factor for a malignancy in patients with dermatomyositis. In this context, our case is a good example that supports the report by Maruani et al.\textsuperscript{6}. The frequency of malignancy in the non-erythrodermic dermatomyositis has been reported to be between 15\% and 45\%,\textsuperscript{6} which is not different from cases of erythrodermic dermatomyositis. Thus, additional evidence is needed to confirm that erythroderma is a predictive factor for a malignancy in patients with dermatomyositis.

Yamashita et al.\textsuperscript{17} reported dermatomyositis as a paraneoplastic manifestation secondary to gastric cancer. In this case, the symptoms of dermatomyositis completely resolved after removal of the tumor without further treatment for dermatomyositis itself. Similar to this report, we can speculate that erythroderma developed as a paraneo-
plastic symptom in the case reported here. However, more data is needed to clarify the relationship of dermatomyositis, erythroderma and internal malignancies. In our case, the long history of systemic skin lesions implied that the erythroderma preceded the gastric cancer and was secondary to the dermatomyositis. Herein we report an additional case of erythrodermic dermatomyositis associated with internal malignancy. Although no precise association has been revealed between erythroderma and internal malignancy in dermatomyositis, additional case reports will be helpful to clarify the relationship.

In conclusion, erythroderma can be a cutaneous manifestation of dermatomyositis; in patients with these findings an internal malignancy should be ruled out.

REFERENCES